87333-19-5 (雷米普利,Ramipril)

雷米普利;N-[1(S)-乙氧羰基-3-苯丙基]-(S)-丙氨酰基-顺桥-2-氮杂二环[3,3,0]辛烷-3(S)-羧酸;雷米普利 ,Ramipril;雷米普利 EP标准品;雷米普利 USP标准品;雷米普利 标准品;雷米普利,USP;雷米普利-D5;(2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(乙氧羰基)-3-苯丙基]氨基]-1-氧代丙基]八氢环戊并[b]吡咯-2-羧酸;雷米普利杂质K;

Ramipril;(2S,3aS,6aS)-1((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester;Altace;Ramipril-d3;(2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]pyrrole-2-carboxylic acid;CARDACE;DELIX;HOE-498;PRAMACE;RAMACE;Trimce;TRITACE;UNIPRIL;vesdil;[2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid;(2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic Acid;(2S,3aS,6aS)-1((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid 1-ethyl ester;(2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ACI);Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2α,3aβ,6aβ]]- (ZCI);Corpril;Ecator;HOE 498;Hopace;MeSH ID: D017257;Ramipres;Rampicardin;Triatec;ramipril impurity K {ramipril diketopiperazine acid};CYCLOPENTA(B)PYRROLE-2-CARBOXYLIC ACID, 1-((2S)-2-(((1S)-1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S,3AS,6AS)-;Ramipril (USP/INN);(2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure;Spectrum5_001721;KBio3_002849;RAMIPRIL (USP MONOGRAPH);BRD-K89348303-001-14-7;AB00698339_09;MFCD00865775;CHEMBL1168;CCG-100833;Ramiprilum (Latin);KBio2_002504;RAMIPRIL [MI];DB00178;Cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-;(2S,3aS,6aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid;STK801937;Pharmakon1600-01505214;(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name);UNII-L35JN3I7SJ;HOE498;MLS001423965;Quark;RAMIPRIL (USP-RS);NC00627;Ramipro;DTXCID203551;Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,6aS)-;RAMIPRIL [USP MONOGRAPH];HMS2051E04;SCHEMBL16059;L35JN3I7SJ;Ramipril, Pharmaceutical Secondary Standard; Certified Reference Material;KBioGR_001858;SPECTRUM1505214;(2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid;Spectrum3_001794;DTXSID8023551;(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid;(2S,3aS,6aS)-1-((S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid;(2S,3aS,6aS)-1-[(S)-N-[(S)-1-Carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, 1-ethyl ester;Tox21_110708_1;HMS2093M10;Naprix;Ramipril (USAN:USP:INN:BAN);Q412666;Tox21_110708;KBioSS_002512;(2S,3As,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]azaniumyl]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylate;HMS3259J07;BBL033964;Ramipril, British Pharmacopoeia (BP) Reference Standard;Carasel;HMS3715M16;BR164319;Ramipril [USAN:USP:INN:BAN];NSC758933;(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid;NSC 758933;RAMIPRIL [EP MONOGRAPH];RAMIPRIL [INN];(2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid;NCGC00016955-01;SR-05000001908-2;Ramipril, United States Pharmacopeia (USP) Reference Standard;Ramipril (1.0 mg/mL in Methanol);RAMIPRIL [VANDF];HSDB 8393;CYCLOPENTA(B)PYRROLE-2-CARBOXYLIC ACID, 1-(2-((1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S-(1(R*(R*)),2.ALPHA.,3A.BETA.,6A.BETA.))-;NS00004700;Altace (TN);(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid;NPD2431;AB00698339-08;RAMIPRIL [WHO-DD];KBio2_005072;NCGC00178127-02;RAMIPRIL [MART.];1-[2-(1-ethoxycarbonyl-3-phenylpropylamino)propionyl]octahydrocyclopenta[b]- pyrrole-2-carboxylic acid;Spectrum_001958;BSPBio_003347;HMS2090L11;NCGC00178127-01;BDBM50084681;RAMIPRIL [JAN];RAMIPRIL, (+)-;CAS-87333-19-5;AB00698339-07;Hytren;1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]pyrrole-2-carboxylic acid(Ramipril);NC00083;Ramipril (Altace);Lostapres;Ramipril, >=98% (HPLC);KS-1103;MLS001216547;87333-19-5;RAMIPRIL (EP MONOGRAPH);RAMIPRIL [USAN];RAMIPRIL (MART.);(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[d]pyrrole-2-carboxylic acid;SR-05000001908;1028843-43-7;Ramiprilum;BIDD:GT0803;HY-B0279;MLS000759523;RAMIPRIL [ORANGE BOOK];AKOS005622534;D00421;Ramipril, European Pharmacopoeia (EP) Reference Standard;N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid;C09AA05;HMS2231M05;CHEBI:8774;EN300-118695;s1793;RAMIPRIL [USP-RS];R0219;SMR000466386;NSC-758933;Spectrum4_001269;Acovil;AB00698339_10;(2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester;Z1515381509;SBI-0206728.P001;(2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-cyclopenta[b]pyrrole-2-carboxylic acid;SR-05000001908-1;GTPL6339;KBio2_007640;AC-1347;Ramiprilum [Latin];

MFCD00865775

HDACQVRGBOVJII-JBDAPHQKSA-N

1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1

C(N1[C@H](C(=O)O)C[C@@H]2CCC[C@H]12)(=O)[C@H](C)N[C@H](C(=O)OCC)CCC1C=CC=CC=1

24724586

3004909090

非巯基血管紧张素转化酶抑制剂,是前体药物,用于肾性及轻、中度及重度原发性高血压,以及中度和恶性充血性心力衰竭。

130g L-丙氨酸苄酯的对甲苯磺酸盐在2.7L 2mol/L****和2.7 L二氯甲烷的溶液进行分配。分出的有机层用无水硫酸钠干燥后,减压蒸去溶剂。剩余的油状物为L-丙氨酸苄酯[化合物(Ⅱ)],将其溶于700ml乙醇待用。另外将51g3-苯甲酰基丙烯酸乙酯[化合物(I)]和7g三乙胺溶于1.9 L乙醇,缓慢加入上面得到的化合物(I)的乙醇溶液。在室温搅拌至少2h,然后冷至0℃。过滤收集结晶,用冷乙醇和石油醚洗,得一份产品。将滤液浓缩后,在50℃下加热1h,再冷至0℃,过滤结晶,可得另一份产品。合计得到的化合物(Ⅲ)的收率为76%,熔点74℃,[α]D20-17.8°(C=1,甲醇)。 20g化合物(Ⅲ)溶于200ml冰乙酸,加入10%钯-炭催化剂,在室温和4MPa的氢压下氢化7h。过滤,滤液浓缩,剩余物溶于小量乙酸乙酯,并用环己烷重结晶,得化合物(Ⅳ),收率90%,熔点148～150℃,[α]D20+28.2°(C=1,甲醇)。 在氮气保持下,将269g 3-氯-2-乙酰胺基丙酸甲酯和257g新蒸馏过的环戊烯基四氢吡咯溶于1....

4214464

MFCD00865775